ES11.05 MSK-IMPACT, a Hospital Based Genetic Screening Using FDA-Approved NGS System

Abstract

A variety of actionable genomic signatures are found across different cancer types. These signatures have been associated with clinical benefit from a variety of therapeutics, including targeted therapy and immunotherapy. MSK-IMPACT is a broad, hybrid capture-based next-generation sequencing platform that is capable of detecting sequence mutations, small insertions and deletions, copy number alterations, and select structural rearrangements. The assay has been validated and approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program. Furthermore, the assay has received authorization by the United States Food and Drug Authority. Comprehensive profiling of various cancers with assays such as MSK-IMPACT has advanced genomic medicine by increasing the identification of patients for whom matched therapies may be appropriate, elucidating putative resistance mechanisms, and identifying novel, potentially actionable signatures. MSK-IMPACT, Next-generation sequencing